MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

Rhea-AI Summary

MaxCyte, a leader in cell-engineering technologies, announced its participation in the William Blair 44th Annual Growth Stock Conference. The event is scheduled for June 5th at 2:40 pm CT. The session will be available live and archived on MaxCyte's investor relations website. MaxCyte focuses on advancing cell-based therapeutics and bioprocessing applications, emphasizing discovery, development, and commercialization.

Positive

• Company's participation in a significant industry event could increase visibility and investor interest.
• The availability of a live and archived webcast allows broader access to the presentation, potentially increasing engagement.

Negative

• The press release lacks detailed financial or clinical data that investors might find useful.
• No new product developments or significant business updates were disclosed, which might not meet investor expectations.

ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the William Blair 44^th Annual Growth Stock Conference on Wednesday, June 5^th at 2:40 pm CT.

A live and archived webcast of the event will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation^® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com

US Media Relations
Spectrum Seismic Collaborative
Anya Bolshem
abolshem@spectrumscience.com

Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500

UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com

FAQ

What event will MaxCyte participate in on June 5th?

MaxCyte will participate in the William Blair 44th Annual Growth Stock Conference on June 5th.

Where can I watch MaxCyte's presentation at the William Blair Growth Stock Conference?

You can watch the live and archived webcast of MaxCyte's presentation on the 'Events' section of their investor relations website.

What time is MaxCyte presenting at the William Blair Growth Stock Conference?

MaxCyte is scheduled to present at 2:40 pm CT on June 5th.

What stock symbol is associated with MaxCyte?

MaxCyte's stock symbol is MXCT.